Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles

Pharmaceutical Research

Volumn 29, Issue 2, 2012, Pages 362-374

  Kong, Won Ho ^a,b   Bae, Ki Hyun ^a   Jo, Sung Duk ^a   Kim, Jee Seon ^a   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Cancer therapy; Cationic lipid; Delivery system; Gold nanoparticle; siRNA

Indexed keywords

CATIONIC LIPID; GOLD NANOPARTICLE; GREEN FLUORESCENT PROTEIN; LIPID; POLYELECTROLYTE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CATION; GOLD; NANOPARTICLE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL CULTURE; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG STABILITY; DRUG UPTAKE; DYNAMIC LIGHT SCATTERING; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIGHT SCATTERING; MICRO-COMPUTED TOMOGRAPHY; PARTICLE SIZE; PRIORITY JOURNAL; STATIC ELECTRICITY; SURFACE CHARGE; SYNTHESIS; ULTRAVIOLET SPECTROSCOPY; CELL SURVIVAL; CHEMISTRY; GENETICS; RNA INTERFERENCE; TUMOR CELL LINE; ULTRASTRUCTURE;

CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; GOLD; HUMANS; LIPIDS; NANOPARTICLES; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84860875427     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0554-y     Document Type: Article

References (39)

1. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60:1307-15.
2. Guo S, Huang Y, Jiang Q, Sun Y, Deng L, Liang Z, et al. Enhanced gene delivery and siRNA silencing by gold nano-particles coated with charge-reversal polyelectrolyte. ACS Nano. 2010;4:5505-11.
3. Lee JS, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 2009;9:2402-6.
4. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc. 2009;131:2072-3.
5. Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A, Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 2009;9:2059-64.
6. Rhim WK, Kim JS, Nam JM. Lipid-gold-nanoparticle hybrid-based gene delivery. Small. 2008;4:1651-5.
7. Li P, Li D, Zhang L, Li G, Wang E. Cationic lipid bilayer coated gold nanoparticles-mediated transfection of mammalian cells. Biomaterials. 2008;29:3617-24.
8. Y. Lee, S.H. Lee, J.S. Kim, A. Maruyama, X. Chen, and T.G. Park. Controlled synthesis of PEI-coated gold nanoparticles using reductive catechol chemistry for siRNA delivery. J Control Release (2010).
9. T. Niidome, K. Nakashima, H. Takahashi, and Y. Niidome. Preparation of primary amine-modified gold nanoparticles and their transfection ability into cultivated cells. Chem Commun (Camb):1978-1979 (2004).
10. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312:1027-30.
11. Kubowicz S, Daillant J, Dubois M, Delsanti M, Verbavatz JM, Mohwald H. Mixed-monolayer-protected gold nanoparticles for emulsion stabilization. Langmuir. 2010;26:1642-8.
12. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008;8:3715-23.
13. Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010;9:272-8.
14. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs. 2010;24:195-205.
15. Gilmore IR, Fox SP, Hollins AJ, Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv. 2006;3:147-5.
16. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 2006;58:467-86. (Pubitemid 43949425)
17. Mokand H, Park TG. Functional polymers for targeted delivery of nucleic acid drugs. Macromol Biosci. 2009;9:731-43.
18. Ohand YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850-62.
19. Mevel M, Kamaly N, Carmona S, Oliver MH, Jorgensen MR, Crowther C, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010;143:222-32.
20. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172-6.
21. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med. 2010;267:9-21.
22. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71:349-58.
23. Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm. 2008;5:622-31.
24. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18:1357-64.
25. Kim SI, Shin D, Lee H, Ahn BY, Yoon Y, Kim M. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol. 2009;50:479-88.
26. Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, et al. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther. 2010;18:1657-66.
27. Zheng N, Fan J, Stucky GD. One-step one-phase synthesis of monodisperse noble-metallic nanoparticles and their colloidal crystals. J Am Chem Soc. 2006;128:6550-1.
28. Brust M. Nanoparticle ensembles: nanocrystals come to order. Nat Mater. 2005;4:364-5. (Pubitemid 40557886)
29. Couto RD, Dallan LA, Lisboa LA, Mesquita CH, Vinagre CG, Maranhao RC. Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids. 2007;42:411-8. (Pubitemid 46870359)
30. Lauer ME, Grassmann O, Siam M, Tardio J, Jacob L, Page S, et al. Atomic force microscopy-based screening of drug-excipient miscibility and stability of solid dispersions. Pharm Res. 2011;28:572-84.
31. Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Takashima H, et al. A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. Mol Cancer Ther. 2003;2:1105-11.
32. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. Journal of controlled release: official journal of the Controlled Release Society. 2008;129:107-16.
33. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. Journal of controlled release: official journal of the Controlled Release Society. 2006;116:123-9.
34. Wu P, Tian Y, Chen G, Wang B, Gui L, Xi L, et al. Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. Cell Death Differ. 2010;17:109-18.
35. Chenand D, Dou QP. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci. 2010;11:459-70.
36. M.F. Yuenand C.L. Lai. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 26 Suppl 1:138-143 (2011).
37. Fu J, Tang ZM, Gao X, Zhao F, Zhong H, Wen MR, et al. Optimal design and validation of antiviral siRNA for targeting hepatitis B virus. Acta Pharmacol Sin. 2008;29:1522-8.
38. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008;25:72-86.
39. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79:248-53.